Humacyte is trading 6.65% up in after-hours trading at $0.59 after releasing second-quarter results and highlighting positive Phase 3 dialysis data.
- Commercial sales were $0.4 million, while EPS of -$0.16 and revenue of $410,000 missed analyst expectations.
- Investors appear to be weighing the earnings shortfall and slower Symvess launch against the planned second-half 2026 dialysis sBLA filing and stronger clinical outlook.